Analysts think EXAS stock price could increase by 32%
Jul 05, 2025, 11:25 AM
0.60%
What does EXAS do
EXACT Sciences, headquartered in Madison, Wisconsin, focuses on cancer screening and diagnostics, employing 6,500 people. Its key products include the Cologuard test for colorectal cancer and Oncotype DX tests for breast cancer.
27 analysts think EXAS stock price will increase by 32.00%. The current median analyst target is $70.44 compared to a current stock price of $53.36. The lowest analysts target is $54.54 and the highest analyst target is $94.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.